SCHEMBL21392408

SCHEMBL21392408

CN1c2ccccc2N(C)c2cc(-c3ccccn3)ccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 1/20 0.44
▸ BACE1 P56817 2/20 0.44
▸ CYP1A2 P05177 2/20 0.43
▸ LMNA P02545 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ CCR1 P32246 1/20 0.43
▸ CCR5 P51681 1/20 0.43
▸ CCR8 P51685 1/20 0.43
▸ METAP1 P53582 1/20 0.43
▸ BLM P54132 1/20 0.43
▸ HIF1A Q16665 1/20 0.43
▸ DOHH Q9BU89 1/20 0.43
▸ P4HTM Q9NXG6 1/20 0.43
▸ HTR1A P08908 1/20 0.43
▸ HTR7 P34969 1/20 0.43
▸ CYP2D6 P10635 1/20 0.41
▸ CYP19A1 P11511 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13507611 0.83 PDK2 (0.41) CYP2A6BACE1CYP1A2LMNAKDM4E
SCHEMBL4085929 0.79 MAOA (0.44) CYP1A2LMNACYP19A1FLT3GSK3B
SCHEMBL19417421 0.76 KDM4E (0.41) BACE1CYP1A2LMNAKDM4EPOLB
SCHEMBL31314329 0.75 GABRA1 (0.41) BACE1CYP1A2LMNAKDM4EPOLB
SCHEMBL5069422 0.75 MAOA (0.41) LMNAKDM4EFLT3GSK3BMAPT
SCHEMBL29679578 0.75 KDM4E (0.62) CYP2A6CYP1A2LMNAKDM4EPOLB
SCHEMBL502867 0.75 KDM4E (0.62) CYP2A6CYP1A2LMNAKDM4EPOLB
SCHEMBL30533680 0.73 KDM4E (0.59) CYP2A6CYP1A2LMNAKDM4EPOLB
SCHEMBL21506994 0.73 KDM4E (0.59) CYP2A6CYP1A2LMNAKDM4EPOLB
Hydrochloric Acid SCHEMBL6007318 0.73 KDM4E (0.59) CYP2A6CYP1A2LMNAKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10886477-B2 Iridium complex and organic electroluminescence device using the same UDC IRELAND LIMITED (IE) 2021-01-05 — — US disclosed
US-20190296251-A1 IRIDIUM COMPLEX AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME LUMINESCENCE TECHNOLOGY CORPORATION (TW) 2019-09-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190296251-A1 IRIDIUM COMPLEX AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME IMPA1, LAGE3, OCIAD1 CYP2A6 4538/4885BACE1 1366/4885CYP1A2 3159/4885
US-10886477-B2 Iridium complex and organic electroluminescence device using the same IMPA1, LAGE3, OCIAD1 CYP2A6 4538/4885BACE1 1366/4885CYP1A2 3159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback